Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalandon, Yves, Sbianchi, Giulia, Gras, Luuk, Koster, Linda, Apperley, Jane, Byrne, Jenny, Salmenniemi, Urpu, Sengeloev, Henrik, Aljurf, Mahmoud, Helbig, Grzegorz, Kinsella, Francesca, Choi, Goda, Reményi, Péter, Snowden, John A., Robin, Marie, Lenhoff, Stig, Mielke, Stephan, Passweg, Jakob, Broers, Annoek E. C., Kröger, Nicolaus, Yegin, Zeynep Arzu, Tan, Sen Mui, Hayden, Patrick J., McLornan, Donal P., Yakoub‐Agha, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092241/
https://www.ncbi.nlm.nih.gov/pubmed/36266607
http://dx.doi.org/10.1002/ajh.26764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092241/
https://www.ncbi.nlm.nih.gov/pubmed/36266607
http://dx.doi.org/10.1002/ajh.26764

Ejemplares similares